Lung Cancer Trials Ask AI to find trials
TerminatedPhase 2NCT02213133
Official study title

Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas

Study summary

Open-label, multi-center, single-arm, Phase 2 study of oral selinexor in patients with SCC of the head and neck (HN-SCC; Cohort 1), lung (L-SCC; Cohort 2), or esophagus (E-SCC; Cohort 3) who have relapsed or have metastasis following chemotherapy.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedSelinexor (KPT-330)

The study team can explain what participation involves.

Who it may be forRecurrent or relapsed · Resistant or refractory

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jan 26, 2023 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?18 U.S. locations

Locations may change over time.

Who runs it?Karyopharm Therapeutics Inc

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 2
Sponsor
Karyopharm Therapeutics Inc
Interventions being studied
Drug: Selinexor (KPT-330)
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting
Recurrent or relapsed→Resistant or refractory→
Treatment approach
Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • 18 years of age or older
  • confirmed SCC of the head and neck, lung, or esophagus
  • 1 to 2 prior therapies
  • measurable disease at screening and documented progression within the past 6 weeks
Reasons someone may not be able to joinExclusion criteria
  • patients requiring total parenteral nutrition
  • unstable cardiovascular function
  • substantially impaired gastrointestinal function
  • Symptomatic brain metastases
  • another malignancy within 3 years except adequately treated in situ carcinoma of any type, basal or non-melanomatous skin cancer

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • University of Colorado Cancer CenterAurora, Colorado
  • Lee Moffitt Cancer Center and Research InstituteTampa, Florida
  • Northwestern UniversityEvanston, Illinois
  • Tufts Medical CenterBoston, Massachusetts
  • Dana-Farber Cancer Institute / Harvard UniversityBoston, Massachusetts
  • Metrowest Medical CenterFramingham, Massachusetts
  • Karmanos Cancer InstituteDetroit, Michigan
  • Washington University School of Medicine / Washington University in St. LouisSt Louis, Missouri
  • Hackensack University Medical CenterHackensack, New Jersey
  • Icahn School of Medicine at Mount SinaiNew York, New York
  • Herbert Irving Comprehensive Cancer Center / Columbia UniversityNew York, New York
  • Gabrail Cancer CenterCanton, Ohio

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 26, 2023. Always confirm current availability with the study team.

View original record ↗